Screening of potential KMO inhibitors

SZ Shaowei Zhang
MS Michiyo Sakuma
GD Girdhar S. Deora
CL Colin W. Levy
AK Alex Klausing
CB Carlo Breda
KR Kevin D. Read
CE Chris D. Edlin
BR Benjamin P. Ross
MM Marina Wright Muelas
PD Philip J. Day
SO Stephen O’Hagan
DK Douglas B. Kell
RS Robert Schwarcz
DL David Leys
DH Derren J. Heyes
FG Flaviano Giorgini
NS Nigel S. Scrutton
ask Ask a question
Favorite

Small-molecule compounds were supplied by Biofocus (Charles River Laboratories International Inc., MA, USA), which were identified in silico as potential inhibitors (further details are described in the Supplementary Methods). Initial inhibition assays were performed against Pseudomonas fluorescens KMO (PfKMO) and Homo sapiens KMO (HsKMO) by monitoring the time-dependent absorbance change of NADPH at 340 nm. Purified KMO protein (200 nM) was incubated in 100 µL reaction buffer (20 mM potassium phosphate pH 8.0, 7 mM 2-mercaptoethanol) containing 100 μM NADPH, 100 μM l-Kyn and 20 μM potential inhibitors in 96-well plates. The change in absorbance at 340 nm was measured using a Synergy™ HT microplate reader (BioTek, VT, USA) for 25 min at 37 °C. The inhibitors identified in the initial screens were validated and re-assayed individually in a 1 cm path-length quartz micro cuvette. IC50 values of potential compounds towards PfKMO or HsKMO <200 μM were considered as indicative of KMO inhibition. Suppliers for target inhibitor compounds are listed in Supplementary Table 11.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A